European stocks slip ahead of US inflation data, GSK jumps
Tech stocks lead morning slide
U.S. inflation data at 1230 GMT
GSK to settle Zantac lawsuits, stock up
Updated at 0825 GMT
By Paolo Laudani and Sruthi Shankar
Oct 10 (Reuters) - European shares slipped on Thursday, with technology and mining stocks leading losses, while investors looked out U.S. inflation data for hints on the Federal Reserve's next policy easing moves.
The pan-European STOXX 600 index .STOXX was down 0.2%, with tech .SX8P, mining .SXPP and travel and leisure .SXTP stocks leading morning declines.
European stocks were under pressureas bondyields rose on Thursday, with the German 10-year yield hitting a fresh one-month high, tracking overnight gains in U.S. Treasury yields. US/
Wall Street indexes touched record highs on Wednesday after the Fed's September meeting minutes showed a "substantial majority" of officials supported an outsized half-point rate cut, without committing to a particular pace of cuts in the future.
Data at 1230 GMT (8:30 a.m. ET) is expected to show U.S. consumer prices rose 0.1% in September on a month-over-month basis, compared with a 0.2% increase in August. Traders are currently pricing in an 85% chance of a smaller 25-basis-point reductionfrom the Fed next month.
"Markets are muted as they're waiting to see what happens with the U.S.CPI (consumer price index) and, more importantly, what's happening on Saturday morning in China," said Stefan Koopman, senior market economist at Rabobank.
"If we get a cooler-than-expected CPI, it won't raise expectations of a 50-basis-point cut; I think the risk is not symmetrical on that report."
The STOXX 600 has been choppy this week as uncertainty around Beijing'sstimulus plans weighed on sentiment. China's finance ministry will detail plans on fiscal stimulus at a highly anticipated news conference on Saturday.
Investors will also focus on the French government's 2025 budget later on Thursday, with plans for 60 billion euros ($65.68 billion) worth of tax hikes and spending cuts to tackle a spiralling fiscal deficit.
Markets are likely to pay close attention to whether the budget can get through parliament without being watered down too much.
"It should be a very credible budget and if it's not, French assets will be at risk tomorrow morning," said Rabobank's Koopman.
Among individual stocks, GSK GSK.L jumped 5.2% after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits in the United States that claimed its discontinued heartburn drug Zantac caused cancer. The figure was smaller than what some analysts had feared.
Shares in Italy's fourth-largest bank BPER EMII.MI rose 7.6% to touch a nine-year high after the lender provided a new 2024-2027 business plan.
Reporting by Paolo Laudani in Gdansk and Sruthi Shankar in Bengaluru; Editing by Eileen Soreng and Sonia Cheema
Aset Terkait
Berita Terbaru
Pengungkapan: Entitas XM Group menyediakan layanan khusus eksekusi dan akses ke Fasilitas Trading Online kami, yang memungkinkan Anda untuk melihat dan/atau menggunakan konten yang tersedia pada atau melalui situs, yang tidak untuk mengubah atau memperluas, serta tidak mengubah atau memperluas hal tersebut. Akses dan penggunaan ini selalu sesuai dengan: (i) Syarat dan Ketentuan; (ii) Peringatan Risiko; dan (iii) Pengungkapan Penuh. Oleh karena itu, konten disediakan hanya sebagai informasi umum. Anda juga harus ketahui bahwa konten Fasilitas Trading Online kami bukan sebagai ajakan atau tawaran untuk untuk melakukan transaksi apa pun di pasar finansial. Trading di pasar finansial mana pun melibatkan tingkat risiko yang signifikan pada modal Anda.
Semua materi yang diterbitkan di Fasilitas Trading Online kami hanya untuk tujuan edukasi/informasi dan tidak boleh mengandung nasihat dan rekomendasi finansial, pajak investasi atau trading, catatan harga trading kami, penawaran, permintaan, transaksi dalam instrumen finansial apa pun atau promo finansial untuk Anda yang tidak diminta.
Konten pihak ketiga apa pun, serta konten yang disiapkan oleh XM, seperti opini, berita, riset, analisis, harga, informasi lain atau link ke situs pihak ketiga yang tersedia "sebagaimana adanya", sebagai komentar pasar umum dan bukan menjadi nasihat investasi. Sejauh konten apa pun ditafsirkan sebagai penelitian investasi, Anda harus memperhatikan dan menerima bahwa konten tersebut tidak dimaksudkan dan belum disiapkan sesuai dengan persyaratan hukum yang dirancang untuk mempromosikan kemandirian riset investasi dan dengan demikian akan dianggap sebagai komunikasi pemasaran di bawah hukum dan peraturan yang relevan. Mohon dipastikan bahwa Anda telah membaca dan memahami Notifikasi pada Riset Investasi Non-Independen dan Peringatan Risiko kami mengenai informasi di atas, yang dapat diakses disini.
